Skip to main content
. Author manuscript; available in PMC: 2020 Oct 3.
Published in final edited form as: Cell Rep. 2020 Sep 22;32(12):108169. doi: 10.1016/j.celrep.2020.108169

Figure 5. R-CV Prevents and Rescues Memory Loss and LTP Impairment in 5xFAD+/− Mice.

Figure 5.

(A and F) The latency to reach the target platform of 3- to 4-month-old (A) and 4- to 5-month-old (F) 5xFAD+/− mice treated with DMSO (3–4 months old, n = 11; 4–5 months old, n = 8) or R-CV (3–4 months old, n = 13; 4–5 months old, n = 10) in the MWM test.

(B and G) The time spent in the target quadrant.

(C and H) The percentage of time spent on the novel object for 5xFAD+/− mice treated with DMSO (3–4months old, n = 11; 4–5 months old, n = 8) or R-CV (3–4 months old, n = 13; 4–5 months old, n = 10).

(D and I) Effect of HFS on mean CA3-CA1 fEPSP slope in hippocampal slices from 5xFAD+/− mice treated with DMSO (3–4 months old, 10 mice, 20 slices; 4–5 months old, 10 mice, 20 slices) or R-CV (3–4 months old, 10 mice, 20 slices; 4–5 months old, 10 mice, 20 slices).

(E and J) The averaged normalized fEPSP slope of 3- to 4-month-old (E) or 4- to 5-month-old (J) 5xFAD+/− mice treated with DMSO or R-CV.

Data shown are the median and range (Mann-Whitney U test; *p < 0.5, **p < 0.01 compared with the DMSO group). See also Figures S5 and S6.

HHS Vulnerability Disclosure